Business News • PR NewsWire • CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma

CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma

CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma

SUZHOU, China, Jan. 8, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) announced that the first patient has been dosed in the Phase III GEMSTONE-304 study of the Company's anti-PD-L1 antibody CS1001 in combination therapy as first-line treatment in...

View More : https://www.prnewswire.com:443/news-releases/cstone-announces-first-patient-dosed-in-the-phase-iii-trial-of-cs1001-in-co...

Releted News by prnewswire

SCA's Christmas Gifts to Cancer Research Foundation, BRIS and Médecins Sans Frontiers

CES 2020: SK hynix Displays its Semiconductor Technologies Leading the 4th Industrial Revolution

TO THE NEW Expands its Footprint in the Middle East With the Opening of its Delivery Center in Dubai

HealthBI Doubled Revenue for CareEmpower Care Coordination Platform in 2019